Finance

Lists
Why is UR9A up 3.64%?
Dive Deeper
UR9A:FRA
Clinuvel Pharmaceuticals Ltd
€4.56
+3.64%
(+0.16) 1D
Oct 21, 8:04:18 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for UR9A...
Open
€4.56
High
€4.56
Low
€4.56
Mkt. cap
372.59M
Avg. vol.
251.00
Volume
0.00
52-wk high
€7.25
52-wk low
€4.30
No. of employees
16
Open
€4.56
High
€4.56
Low
€4.56
Mkt. cap
372.59M
Avg. vol.
251.00
Volume
0.00
52-wk high
€7.25
52-wk low
€4.30
No. of employees
16
News stories
From web sources and news partners
About Clinuvel Pharmaceuticals Ltd
CEOPhilippe J. Wolgen
Employees16
Founded1987
Headquarters-
SectorBiotechnology
Websiteclinuvel.com
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
18.47M
18.47M
28.55M
28.55M
Cost of goods sold
2.28M
2.28M
5.62M
5.62M
Cost of revenue
2.28M
2.28M
5.62M
5.62M
Research and development expenses
1.70M
1.70M
7.35M
7.35M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.96M
6.96M
2.83M
2.83M
Operating expense
9.42M
9.42M
9.42M
9.42M
Total operating expenses
11.71M
11.71M
15.04M
15.04M
Operating income
6.76M
6.76M
13.51M
13.51M
Other non operating income
-
-
322.45K
322.45K
EBT including unusual items
7.29M
7.29M
16.54M
16.54M
EBT excluding unusual items
7.29M
7.29M
16.54M
16.54M
Income tax expense
2.07M
2.07M
4.80M
4.80M
Effective tax rate
28.39%
28.39%
29.03%
29.03%
Other operating expenses
-1.24K
-1.24K
1.24K
1.24K
Net income
5.22M
5.22M
11.74M
11.74M
Net profit margin
28.28%
28.28%
41.11%
41.11%
Earnings per share
-
-
-
-
Interest and investment income
2.63M
2.63M
3.87M
3.87M
Interest expense
-1.28M
-1.28M
-
-
Net interest expenses
1.35M
1.35M
3.87M
3.87M
Depreciation and amortization charges
250.02K
250.02K
-250.02K
-250.02K
EBITDA
7.01M
7.01M
13.55M
13.55M
Gain or loss from assets sale
-
-
28.62K
28.62K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps